PSMC2

Across TCGA pan-cancer cohorts, PSMC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMC2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PSMC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSMC2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, OV, and PDAC are the cancer types where PSMC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	1.000	0.903	.004	19	view →
OV	DFS	Quartile	All	0.651	1.000	.042	8	view →
PDAC	DFS	Quartile	III,IV	0.498	0.979	.006	8	view →
LUAD	OS	Tertile	All	0.617	0.891	.002	8	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMC2–HNSC (DFS)

Open the HNSC breakdown →